Pittsburgh Pharmacy Investment Portfolio

Pharmaceutical companies have historically struggled with negative public perception. In January 2020, before the COVID-19 pandemic, only...

On Thursday, February 26th Merck announced that it will pay out roughly $1.85 billion to acquire Pandion Therapeutics, a biotech hoping...

In recent weeks, the stock market has seen an unprecedented battle between two powerhouse groups. The first being a hedge fund by the...

Supernus Pharmaceuticals is a small(ish)-cap specialty pharmaceuticals company that is largely involved in neuroscience and psychiatry....

The Pittsburgh Pharmacy Investment Portfolio (PPIP) wrapped up its Biotech Investment Fantasy League (BIFL) competition at its annual...

On November 16th, 2020 Moderna, who has never had a drug or vaccine go to market, has announced efficacy data on the COVID-19 vaccine...

Aducanumab is a monoclonal antibody that selectively targets and decreases levels of the amyloid beta plaques that are a hallmark of...

On October 22nd, 2020, The FDA approved Gilead Science’s antiviral medication, remdesivir, as a COVID-19 treatment for patients requiring...

What is an orphan drug? Rare diseases are defined by the Food and Drug Administration and are based on the size of the patient population...

Merck makes up approximately 6.5% of Pittsburgh Pharmacy Investment Portfolio’s holdings. PPIP bought 76 shares of Merck at a price of...

As members of the Pittsburgh Pharmacy Investment Portfolio (PPIP), student pharmacists utilize the clinical knowledge that we learn in...

This past week, 21 of our PPIP analysts made recommendations to change or keep our current portfolio holdings. Details regarding changes...

This week in pharma: Arbor took a novel marketing approach by recruiting former NBA basketball star Shaquille O’Neal as the face of the...

This week in pharma, AbbVie is showing signs of a strong year. Skyrizi, their, recent collaboration with Boehringer Ingelheim, just got...

This week in pharma: On Tuesday, March 19, the FDA approved the first postpartum depression drug brexanolone (Zulresso—Sage...

Big news this week in pharma! the Trump administration appointed Dr. Ned Sharpless as the interim director of the FDA after Former...

This week in pharma: Johnson & Johnson’s esketamine, or Spravato, won the agency approval on Tuesday, March 5, 2019. Spravato is a nasal...

This week in Pharma, Akron Pharmaceuticals, which recently received 2 FDA manufacturing warnings, got hit with a form 483 for stability...

This week in pharma: Merck announced their data from three pivotal phase 3 trials focusing on treating advanced prostate cancer. The...

This week in pharma, the FDA approved the first generic biosimilar of GSK's big seller Advair. Although GSK has been working with Part D...